Adverse events (pain) · adults requiring radial artery catheterisation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults requiring axillary artery catheterisation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults requiring radial artery catheterisation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
First‐attempt success rate · adults requiring dorsalis pedis artery catheterisation
It is very uncertain whether [Dorsalis pedis] B‐mode ultrasound guidance changes first‐attempt success rate compared with palpation and landmarks (very low certainty).
1 finding from 1 review
Pseudoaneurysm · adults requiring dorsalis pedis artery catheterisation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality · CVD (ASCVD, HF, or both)
DPP4i showed no clear difference in cardiovascular mortality compared with placebo (high certainty).
1 finding from 1 review
Cardiovascular mortality · CVD (ASCVD, HF, or both)
GLP‐1RA leads to lower cardiovascular mortality compared with placebo (high certainty).
1 finding from 1 review
Fatal or nonfatal myocardial infarction · CVD (ASCVD, HF, or both)
GLP‐1RA showed no clear difference in myocardial infarction (fatal or non‐fatal) compared with placebo (moderate certainty).
1 finding from 1 review
Fatal or nonfatal stroke · CVD (ASCVD, HF, or both)
GLP‐1RA leads to lower stroke (fatal or non‐fatal) compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality · CVD (ASCVD, HF, or both)
GLP‐1RA leads to lower all‐cause mortality compared with placebo (high certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · CVD (ASCVD, HF, or both)
GLP‐1RA showed no clear difference in hospitalisation for HF compared with placebo (high certainty).
1 finding from 1 review
Worsening kidney function · CVD (ASCVD, HF, or both)
GLP‐1RA may leads to lower worsening renal function compared with placebo (low certainty).
1 finding from 1 review
Hypoglycaemia · CVD (ASCVD, HF, or both)
1 finding from 1 review
Pancreatitis · CVD (ASCVD, HF, or both)
GLP‐1RA showed no clear difference in pancreatitis compared with placebo (low certainty).
1 finding from 1 review
Fracture · CVD (ASCVD, HF, or both)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality · CVD (ASCVD, HF, or both)
SGLT2i probably leads to lower cardiovascular mortality compared with placebo (moderate certainty).
1 finding from 1 review
Fatal or nonfatal myocardial infarction · CVD (ASCVD, HF, or both)
DPP4i showed no clear difference in myocardial infarction (fatal or non‐fatal) compared with placebo (high certainty).
1 finding from 1 review
Fatal or nonfatal myocardial infarction · CVD (ASCVD, HF, or both)
SGLT2i showed no clear difference in myocardial infarction (fatal or non‐fatal) compared with placebo (high certainty).
1 finding from 1 review
Fatal or nonfatal stroke · CVD (ASCVD, HF, or both)
SGLT2i showed no clear difference in stroke (fatal or non‐fatal) compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · CVD (ASCVD, HF, or both)
SGLT2i probably leads to lower all‐cause mortality compared with placebo (moderate certainty).
1 finding from 1 review